Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
AXSM Transcript
Axsome Therapeutics, Inc. (AXSM) Q4 2025 Earnings Call Transcript
Positive2-23
The earnings call highlights strong prescription growth for key products like AUVELITY and SUNOSI, successful launch of SYMBRAVO, and promising pipeline developments. The Q&A reveals positive analyst sentiment towards growth drivers and market opportunities, despite some unclear management responses. The strategic plan indicates expansion and potential new approvals, suggesting future growth. The market cap of $3.8 billion suggests moderate sensitivity to news. Overall, the combination of strong current performance and optimistic future guidance justifies a positive stock price outlook over the next two weeks.
Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Neutral12-4
Axsome Therapeutics, Inc. (AXSM) Q3 2025 Earnings Call Transcript
Positive11-3
The earnings call summary indicates strong progress in product development, with multiple Phase III trials and regulatory submissions on track. The Q&A section highlights positive growth trends and strategic plans, although some details were withheld. The market cap suggests a moderate reaction. Considering the strategic plans, strong product pipeline, and positive indications from the Q&A, a positive stock price movement of 2% to 8% is expected over the next two weeks.
Axsome Therapeutics, Inc. (AXSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-8
AXSM Slides
Axsome Q4 2025 slides: revenue surges 66%, stock dips on expenses2026-02-23
Axsome Therapeutics Q3 2025 slides: Strong revenue growth amid pipeline expansion2025-11-03
Axsome Q2 2025 slides: revenue surges 72% YoY, pipeline advances on track2025-08-04
Axsome Q1 2025 slides: 62% revenue growth as CNS portfolio expands2025-05-05
AXSM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
